Clinical and immunoserological characteristics of the transition from primary to overlap antiphospholipid syndrome

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Antiphospholipid syndrome (APS) is a distinct clinical entity characterized by arterial and venous thromboembolic events, recurrent fetal loss and the presence of antiphospholipid antibodies in the patientsg' sera. In primary APS, there is no detectable underlying disease, while overlap APS is associated with clinical syndromes including systemic autoimmune diseases, infections, or malignancies. We carried out a retrospective analysis of serological and clinical manifestations as well as assessed outcome-measures in 165 patients with primary APS. Thrombotic manifestations and possible signs of autoimmune diseases were determined at the time of the diagnosis, followed by the analysis of recurrent thrombotic events and effects of therapy during the follow-up period. Among the 165 patients with primary APS at onset, 105 patients (63%) remained primary APS after a mean 5.2 years of follow-up. In 14% of the patients, subsequently APS became associated with various characteristics of undifferentiated connective tissue disease. Finally 23% of patients evolved into a definitive systemic autoimmune disease during a mean 9.75 years of follow-up. Recurrent thrombotic events were registered in 24% of patients. Our results suggest that primary APS may be considered as a potential early phase of a dynamic transition towards a well-defined systemic autoimmune disease.

Original languageEnglish
Pages (from-to)1520-1526
Number of pages7
JournalLupus
Volume19
Issue number13
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Antiphospholipid Syndrome
Autoimmune Diseases
Antiphospholipid Antibodies
Connective Tissue Diseases
Outcome Assessment (Health Care)
Infection
Serum

Keywords

  • primary and overlap antiphospholipid syndrome
  • recurrent thrombotic events
  • retrospective study

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{df2f0bcf8ec04684846a853a55ac0cfe,
title = "Clinical and immunoserological characteristics of the transition from primary to overlap antiphospholipid syndrome",
abstract = "Antiphospholipid syndrome (APS) is a distinct clinical entity characterized by arterial and venous thromboembolic events, recurrent fetal loss and the presence of antiphospholipid antibodies in the patientsg' sera. In primary APS, there is no detectable underlying disease, while overlap APS is associated with clinical syndromes including systemic autoimmune diseases, infections, or malignancies. We carried out a retrospective analysis of serological and clinical manifestations as well as assessed outcome-measures in 165 patients with primary APS. Thrombotic manifestations and possible signs of autoimmune diseases were determined at the time of the diagnosis, followed by the analysis of recurrent thrombotic events and effects of therapy during the follow-up period. Among the 165 patients with primary APS at onset, 105 patients (63{\%}) remained primary APS after a mean 5.2 years of follow-up. In 14{\%} of the patients, subsequently APS became associated with various characteristics of undifferentiated connective tissue disease. Finally 23{\%} of patients evolved into a definitive systemic autoimmune disease during a mean 9.75 years of follow-up. Recurrent thrombotic events were registered in 24{\%} of patients. Our results suggest that primary APS may be considered as a potential early phase of a dynamic transition towards a well-defined systemic autoimmune disease.",
keywords = "primary and overlap antiphospholipid syndrome, recurrent thrombotic events, retrospective study",
author = "K. Veres and P. Szodoray and Z. Szekanecz and G. Lakos and E. Kiss and R. Laczik and S. Sipka and E. Bodolay and M. Zeher and L. Muszbek and G. Szegedi and P. Solt{\'e}sz",
year = "2010",
month = "11",
doi = "10.1177/0961203310374336",
language = "English",
volume = "19",
pages = "1520--1526",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "13",

}

TY - JOUR

T1 - Clinical and immunoserological characteristics of the transition from primary to overlap antiphospholipid syndrome

AU - Veres, K.

AU - Szodoray, P.

AU - Szekanecz, Z.

AU - Lakos, G.

AU - Kiss, E.

AU - Laczik, R.

AU - Sipka, S.

AU - Bodolay, E.

AU - Zeher, M.

AU - Muszbek, L.

AU - Szegedi, G.

AU - Soltész, P.

PY - 2010/11

Y1 - 2010/11

N2 - Antiphospholipid syndrome (APS) is a distinct clinical entity characterized by arterial and venous thromboembolic events, recurrent fetal loss and the presence of antiphospholipid antibodies in the patientsg' sera. In primary APS, there is no detectable underlying disease, while overlap APS is associated with clinical syndromes including systemic autoimmune diseases, infections, or malignancies. We carried out a retrospective analysis of serological and clinical manifestations as well as assessed outcome-measures in 165 patients with primary APS. Thrombotic manifestations and possible signs of autoimmune diseases were determined at the time of the diagnosis, followed by the analysis of recurrent thrombotic events and effects of therapy during the follow-up period. Among the 165 patients with primary APS at onset, 105 patients (63%) remained primary APS after a mean 5.2 years of follow-up. In 14% of the patients, subsequently APS became associated with various characteristics of undifferentiated connective tissue disease. Finally 23% of patients evolved into a definitive systemic autoimmune disease during a mean 9.75 years of follow-up. Recurrent thrombotic events were registered in 24% of patients. Our results suggest that primary APS may be considered as a potential early phase of a dynamic transition towards a well-defined systemic autoimmune disease.

AB - Antiphospholipid syndrome (APS) is a distinct clinical entity characterized by arterial and venous thromboembolic events, recurrent fetal loss and the presence of antiphospholipid antibodies in the patientsg' sera. In primary APS, there is no detectable underlying disease, while overlap APS is associated with clinical syndromes including systemic autoimmune diseases, infections, or malignancies. We carried out a retrospective analysis of serological and clinical manifestations as well as assessed outcome-measures in 165 patients with primary APS. Thrombotic manifestations and possible signs of autoimmune diseases were determined at the time of the diagnosis, followed by the analysis of recurrent thrombotic events and effects of therapy during the follow-up period. Among the 165 patients with primary APS at onset, 105 patients (63%) remained primary APS after a mean 5.2 years of follow-up. In 14% of the patients, subsequently APS became associated with various characteristics of undifferentiated connective tissue disease. Finally 23% of patients evolved into a definitive systemic autoimmune disease during a mean 9.75 years of follow-up. Recurrent thrombotic events were registered in 24% of patients. Our results suggest that primary APS may be considered as a potential early phase of a dynamic transition towards a well-defined systemic autoimmune disease.

KW - primary and overlap antiphospholipid syndrome

KW - recurrent thrombotic events

KW - retrospective study

UR - http://www.scopus.com/inward/record.url?scp=78649285727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649285727&partnerID=8YFLogxK

U2 - 10.1177/0961203310374336

DO - 10.1177/0961203310374336

M3 - Article

C2 - 20685773

AN - SCOPUS:78649285727

VL - 19

SP - 1520

EP - 1526

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 13

ER -